Burning Rock Biotech vs Castle Biosciences
BNR and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and CSTL compare
Castle Biosciences grew revenue faster over the last twelve months (9.8% versus 4.6% for Burning Rock Biotech).
Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −10.3% at Burning Rock Biotech.
Castle Biosciences scores higher on the StockData Score (11 against 5 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | CSTL |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.0B |
| Share price | $13.29 | $33.79 |
| Change, 1 year | 8.8% | −3.0% |
| Change, 5 years | −92.2% | −28.9% |
| Beta (5Y) | 1.73 | 1.38 |
| Employees | 667 | 883 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.7× |
| P/B | – | 2.2× |
| P/FCF | – | 260× |
| FCF yield | – | 0.38% |
| Fair value | – | $34.71 |
| Margin of safety | – | 2.6% |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 9.8% (better) |
| Revenue growth, 5Y average | 4.6% | 40.6% (better) |
| Profitability | ||
| Gross margin | 74.7% | 77.1% (better) |
| Operating margin | −10.2% | −7.4% (better) |
| Net margin | −10.3% | −6.1% (better) |
| FCF margin | −6.2% | 1.1% (better) |
| Return on equity | −9.9% | −4.9% (better) |
| Return on invested capital | −72.5% | −11.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.02 |
| Interest coverage | – | −51.2× |
| Current ratio | 2.99 | 5.28 (better) |
| Altman Z-score | – | 6.63 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.8% | 89.5% |
| Held by insiders | 19.0% | 1.9% |
| Insider net buying, 12 months | $11.6M (better) | −$18.3M |
| Short interest, % of float | – | 7.0% |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.